Redcliffe Lifetech launches multiplex RT-PCR test to diagnose mucormycosis

Redcliffe Lifetech launches multiplex RT-PCR test to diagnose mucormycosis

The molecular diagnostics company Redcliffe Lifetech, has introduced a non-invasive (serum/fluid) RT-PCR test to detect the DNA of mucorales species causing mucormycosis or black fungus.

As a part of the diagnostic process, bronchoalveolar lavage (BAL) samples will be used to directly detect the infection, with sample-to-result collection in less than 24 hours.

The company also said that various samples including bronchoalveolar lavage (BAL) samples, biopsy samples, paraffin embedded serum samples will be collected to detect the potential health disorder or diseases in people. The diagnosis of mucormycosis will target mucormycetes, rhizopus spp., mucor spp., lichtheimis spp., cunninghamella spp. and rhizomucor spp.

The company has announced that the test is priced at Rs 7,000.

Commenting on the announcement, Dheeraj Jain, Managing Director, Redcliffe Lifetech said, “We endeavour to assist the Government of India and the general public in combating this deadly infection with the most advanced approach. With the help of our technology, we can assist them in a timely diagnosis of mucormycosis. This will undoubtedly aid in the diagnosis and treatment of patients.”

Mucormycosis generally affects people with comorbid conditions taking immunosuppressant steroid medications to manage pre-existing illnesses as well as COVID-19, over an extended length of time or those with diabetes mellitus who are unable to keep blood sugar levels within the normal range. It also believed that being treated in the Intensive Care Unit i.e. ICU wing of hospitals for a prolonged interval of time. Having a vulnerable immune system that is weakened owing to comorbidities such as previous organ transplant surgeries or cancer therapy procedures or those already taking prescription antifungal drugs to combat infections are prone to get infected.